Resources from the same session
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
Presenter: Mark Glaire
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial
Presenter: Pierre Laurent-Puig
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
Invited discussant abstracts 456O, 457O and 458O
Presenter: Chiara Cremolini
Session: Gastrointestinal tumours, colorectal 2
Resources:
Presentation
Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor
Presenter: Gunnar Folprecht
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
Presenter: Pierre Laurent-Puig
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial
Presenter: Francois-Clement Bidard
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation
Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
Presenter: Julien Taieb
Session: Gastrointestinal tumours, colorectal 2
Resources:
Abstract
Presentation